Transplant Diagnostics Market Research Report- Global Forecast Till 2023

Transplant Diagnostics Market Research Report- Global Forecast Till 2023

ID: MRFR/HC/0816-CRR | July, 2018 | Region: Global | 100 pages | Cooked Research Reports

Global Transplant Diagnostics Market Information, Product & Service (Instruments, Reagents & Consumables), Screening Type (Pre-Transplant, Post-Transplant), Organ Type (Kidney, Liver, Heart, Lung, Pancreas), Application Type, End-User – Forecast to 2023


The rise in chronic diseases has elicited the demand for assays capable of diagnosing histocompatibility prior to transplantation. The global transplant diagnostics market size is anticipated to touch USD 2,074.65 million by 2023, as per an in-depth report by Market Research Future (MRFR). It is predicted to experience a 7.80% CAGR during the assessment period (2018-2023) driven by recent advancements in transplant diagnostics.


The recent rise in funding to research institutes for target research purposes made possible by public-private partnerships can bolster market growth over the forecast period. Transplant diagnostics can play a major role in reducing the rate of organ rejection among adults. The emergence of China and India as hubs for low-cost transplantation procedures can provide an impetus to the market growth. But low awareness among patients coupled with stringent regulations can hamper the market.


Report Overview


This report covers current events and trends in the market for transplant diagnostics to provide the most accurate forecasts and predictions. By correlating the historical data with key market dynamics, our analysts are able to make highly accurate projections. MRFR’s report includes a thorough analysis of the global transplant diagnostics market segmented on the basis of product & service, screening type, organ type, application type, end-user, and region with astute insights. The report has been prepared to assist industry players in making the right decisions which can culminate in fruitful returns. Users will also come across drivers, trends, opportunities, and restraints which are likely to influence the growth of the market during the assessment period.


Segment Overview


By product & sevice, the transplant diagnostics market comprises instruments, reagents & consumables, and software & services. The reagents and consumables segment accounted for a large market share in 2017. It can continue to be lucrative for the market during the forecast period. The two major types of screening covered in the market report include pre-transplant screening and post-transplant screening. Organs screened with the aid of transplant diagnostics include lung, pancreas, heart, liver, kidney, and others.


Major market applications include diagnostic applications, research applications, and others. End-users of the product comprises hospitals and transplant centers, commercial service providers, research laboratories & academic institutes, and others. The hospitals and transplant centers segment is likely to be the biggest end-user till the end of the assessment period owing to demand for diagnosis of infectious diseases.


The segments and sub-segments covered in the report are analyzed under five major regions – Americas, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The standard definition of the product “transplant diagnostics” is included in the report for a comprehensive understanding of the market. The report discusses and interprets the current trends and future opportunities of the market by delivering an unbiased growth assessment.


Players Covered


Bio-Rad Laboratories, Inc., Illumina, Inc., Thermo Fisher Scientific Inc., F. Hoffmann La Roche Ltd., Becton Dickinson and Company, bioMérieux S.A., QIAGEN N.V., and others are reputed players currently operational in the transplant diagnostics market. The demand for astute and improved diagnostic techniques is expected to culminate in innovation in products. This can lead to price wars among the players and encourage investments in research and development.


The report offers comprehensive profiles on these market players and assesses their current standing in the transplant diagnostics market. Company history coupled with annual turnover, segmental share, SWOT analysis, growth strategies, new product launches, mergers and acquisitions (M&A) activities, and latest R&D initiatives are outlined in the report.


Research Methodology


Market Research Future (MRFR) employ a selective body of methods which assist in a scientific and systematic approach to research of the given field of study. Primary methods such as interviews with decision makers of leading competitors in the market have been used along with secondary methods to provide a comprehensive view of the market scenario. Credible sources such as white papers, annual reports, and SEC filings have been used as a part of objective secondary research methods. Top-down and bottom-up approaches have been applied to the field of study to provide accurate estimation and validation of the market. Inquisitive and proficient data analysts exhaust every line of research based on pertinent parameters to offer intelligent inputs and a dependable understanding of the market in its entirety.


Analysis Period



  • Base Year - 2017

  • Projection Period - From 2018 to 2023

  • Market Denomination - USD Million

  • Conversion Rate - Considered as per the respective financial years


For the scope of research, the report offers a comprehensive analysis of the global transplant diagnostics market.


Product & Service



  • Instruments

  • Reagents & Consumables

  • Software & Services


Screening Type



  • Pre-transplant Screening

  • Post-transplant Screening


Organ Type



  • Kidney

  • Pancreas

  • Liver

  • Heart

  • Lungs

  • Others


Application Type



  • Research Applications

  • Diagnostic Applications

  • Others


End-user



  • Commercial Service Providers

  • Hospitals & Transplant Centers

  • Research Laboratories & Academic Institutes

  • Others


Region



  • Americas

  • Europe

  • Asia Pacific (APAC)

  • The Middle East & Africa (MEA)


Intended Audience



  • Associations

  • End Users

  • Pharmaceutical Companies

  • Raw Material Suppliers

  • Suppliers and Distributors

  • Transplant Diagnostics Kits Manufacturers

  • Government

  • Potential Investors

Global Transplant Diagnostics Market – Summary


The global transplant diagnostics market is touted to scale the valuation of USD 2,074.65 million during the forecast period (2018-2023), reveals insightful reports of Market Research Future (MRFR). Technological advancements have reduced the healthcare cost and have taken the medical industry miles ahead by helping researchers and doctors in implementing new methods to cure patients. Consequently, this is also going to aid the market in achieving a splendid CAGR of 7.81% by 2023.


Rapid urbanization, along with industrialization moving at express speed, has given rise to expendable incomes among patients. Well-being awareness among the populace has also increased. Thus, as a resultant factor, increase in investment in this sector can be witnessed. People are now more willing to improve the quality of their lives by getting transplantation of numerous human cells, tissues, and organs. According to reports published, in collaboration, by World Health Organization (WHO) and Spain-based Organización Nacional de Trasplantes (ONT), 126,670 organs were transplanted in 2015, of which 41.80% was of the kidney category. In North America, the number was around an astounding 19,484 in 2017. The staggering numbers reveal a much more comprehensive picture of the market and promise future prosperity.


With rising population, critical diseases are also experiencing a surge, which as an upshot is triggering increasing cases of organ failures. For instance, renal diseases can occur due to high blood pressure and diabetes and as a corollary effect, kidney transplant or dialysis becomes imperative.


The past few years have also noted remarkable progress in tissue engineering. However, the achievement has been marred by the shortage of human hepatocytes directly disturbing the said technological advancement. Furthermore, post and intra operative complication risks are also very high due to its complex execution. These factors could pose as market deterrents. 


Segmentation:


The global market for transplant diagnostic can be segmented by product & service, screening type, organ type, application type, and end-user.


By product & service, the market includes reagents & consumables, and software and services. Diagnostic tests are experiencing innovations across the world and the reason behind the market dominance of reagents & consumables. The market scenario is expected to remain so during the forecast period.


Based on screening type, the market is segmented into pre-transplant and post-transplant screening. Pre-transplant screening had a market valuation of USD 819.04 million in 2017, and the market is expected to reign supreme in the foreseeable future.


Application-wise, the market comprises research applications, diagnostic applications, and others. Favorable government policies have made it easier for companies to get their latest products approved quicker than before. In addition, advents in surgical techniques have facilitated and cemented the market leader’s spot for diagnostic applications. In 2017, this sector was valued at over USD 727.44 million, and the trend is expected to remain the same in coming years.


On the basis of organ type, the market comprises segments such as kidney, liver, heart, lung, pancreas, and others. The kidney segment was valued at USD 819.04 million in 2017 and was the highest among its peers, and its domination is expected to continue during the review period as well.


Based on end-users, the market is segmented into commercial service providers, hospitals & transplant centers, research laboratories & academic institutes, and others. The financial crunch has led many companies to outsource diagnosis testing to hospitals & transplant centers, which has paid off well for the sector’s growth and has made it the current market leader. The scenario is expected to remain the same during the assessment period.


Regional Analysis:


Geographically, the market covers the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).


The Americas are currently dominating the market. Factors such as the prevalence of chronic diseases, progress in the field of human leukocyte antigen (HLA) typing, development of robot-assisted laboratory automation of diagnostic procedures, and growing number of solid, stem cell, and soft tissue based transplantations are boosting the regional market.


Europe accounted for the second largest market. The World Health Organization (WHO) is planning to spread awareness through policies such as WHA57.18 in the region that can boost the sector further in the future.


The APAC is expected to register an astounding growth due to the population demography. Rising number of patients and increasing demand for transplant can act in favor of the market. Also, the region is investing heavily in stem cells to develop organs and in-vitro tissue which have constructive impacts on the market. Along with these factors, the Philippines, Thailand, Indonesia, and India can play significant roles during the forecast period.


Market Dashboard:


A number of factors such as demand for cosmetic and reconstructive surgery, high growth in geriatric population, technological advancements, and the decrease in chances of tissue or organ rejection can impact the transplant diagnostics market. Tissue engineering has proved to be more modern and interdisciplinary in comparison with plastic surgery which can give prove beneficial for the market.


Key players involved in the global transplant diagnostics market are Thermo Fisher Scientific Inc., F. Hoffmann La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Illumina, Inc., bioMérieux S.A., Becton Dickinson and Company, and others.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

TABLE OF CONTENTS

3.1 Scope of Study 25

3.2 Research Objective 25

3.3 List of Assumptions 25

3.4 Market Structure 26

4.1 Primary Research Methodology 29

4.2 Data points received from the Specialist Doctors: 29

4.3 Data points received from the Manufacturer/ Pharmaceutical Companies: 30

4.4 Data points received from Hospitals, Diagnostic Centers: 31

4.5 Secondary Research Methodology 32

4.6 Market Share Analysis 33

4.7 Trade Analysis 34

4.8 Market Pricing Approach 34

4.9 Forecast Model 35

5.1 Introduction 37

5.2 Drivers 38

5.2.1 Growing number of stem cell, soft-tissue, and solid organ, transplantation procedures 38

5.2.2 Rising occurrence of chronic and infectious diseases 38

5.2.3 Increasing Awareness Related to Transplant Diagnostic Procedures 38

5.3 Restraints 39

5.3.1 Shortage of donor organ and limited medical reimbursement 39

5.3.2 High cost of NGS- and PCR-based devices 39

5.4 Opportunities 40

5.4.1 High demand for tissue engineering in cosmetic and reconstructive surgery 40

5.4.2 Growing geriatric population presents a significant growth opportunity 40

6.1 Porters Five Forces Analysis 42

6.1.1 Bargaining Power of Suppliers 42

6.1.2 Bargaining Power of Buyers 43

6.1.3 Threat of New Entrants 43

6.1.4 Threat of Substitutes 43

6.1.5 Intensity of Rivalry 43

6.2 Supply Chain Analysis 44

6.2.1 Primary activities 44

6.2.2 Secondary Activities 45

7.1 Overview 47

7.1 Diagnostic Tests for Transplantation 47

7.1.1 Therapeutic Drug Monitoring During Transplantation 47

7.2 Americas 48

7.2.1 North America 48

7.2.2 South America 52

7.3 Europe 53

7.3.1 Germany 54

7.3.2 U.K 55

7.3.3 France 56

7.3.4 Spain 57

7.3.5 Italy 58

7.3.6 Rest of Europe 59

7.4 Asia Pacific 61

7.4.1 China 62

7.4.2 Japan 63

7.4.3 India 64

7.4.4 Australia 65

7.4.5 Rest of Asia Pacific 66

7.5 Middle East & Africa 68

7.5.1 Middle East 69

7.5.2 Africa 70

8.1 Introduction 73

8.1.1 Instruments 75

8.1.2 Reagents & Consumables 76

8.1.3 Software and Services 76

9.1 Introduction 78

9.1.1 Pre-Transplant Screening 79

9.1.2 Post-Transplant Screening 79

10.1 Introduction 81

10.1.1 Kidney 82

10.1.2 Liver 82

10.1.3 Heart 83

10.1.4 Lung 83

10.1.5 Pancreas 83

11.1 Introduction 85

11.1.1 Research Applications 86

11.1.2 Diagnostic Applications 86

12.1 Introduction 88

12.1.1 Commercial Service Providers 89

12.1.2 Hospitals and Transplant Centres 89

12.1.3 Research Laboratories and Academic Institutes 89

13.1 Introduction 91

13.2 Americas 92

13.2.1 North America 93

13.2.2 South America 104

13.3 Europe 108

13.3.1 Germany 112

13.3.2 U.K 116

13.3.3 France 119

13.3.4 Spain 123

13.3.5 Italy 126

13.3.6 Rest of Europe 130

13.4 Asia Pacific 134

13.4.1 China 138

13.4.2 Japan 142

13.4.3 India 145

13.4.4 Australia 149

13.4.5 Rest of Asia Pacific 152

13.5 Middle East & Africa 156

13.5.1 Middle East 160

13.5.2 Africa 164

14.1 Company Market Share Analysis 169

14.1.1 Introduction 169

14.2 Competitive Landscape 170

14.2.1 Introduction 170

14.3 Key Developments 171

15.1 Thermo Fisher Scientific Inc. 175

15.1.1 Company Overview 175

15.1.2 Financial Overview 175

15.1.3 Products Offering 176

15.1.4 Key Developments 176

15.1.5 SWOT Analysis 176

15.1.6 Key Strategy 177

15.2 Bio-Rad Laboratories, Inc. 178

15.2.1 Company Overview 178

15.2.2 Financial Overview 178

15.2.3 Products Offering 179

15.2.4 Key Developments 179

15.2.5 SWOT Analysis 179

15.2.6 Key Strategy 180

15.3 F. Hoffmann-La Roche AG 181

15.3.1 Company Overview 181

15.3.2 Financial Overview 181

15.3.3 Products Offering 182

15.3.4 Key Developments 182

15.3.5 SWOT Analysis 183

15.3.6 Key Strategy 183

15.4 Qiagen N.V. 184

15.4.1 Company Overview 184

15.4.2 Financial Overview 184

15.4.3 Products Offering 185

15.4.4 Key Developments 185

15.4.5 SWOT Analysis 185

15.4.6 Key strategy 185

15.5 BioMérieux SA 186

15.5.1 Company Overview 186

15.5.2 Financial Overview 186

15.5.3 Products Offering 187

15.5.4 Key Developments 187

15.5.5 SWOT Analysis 187

15.5.6 Key Strategy 187

15.6 Illumina, Inc. 188

15.6.1 Company Overview 188

15.6.2 Financial Overview 188

15.6.3 Products Offering 189

15.6.4 Key Developments 189

15.6.5 SWOT Analysis 190

15.6.6 Key Strategy 190

15.7 Becton, Dickinson and Company 191

15.7.1 Company Overview 191

15.7.2 Financial Overview 191

15.7.3 Products Offering 192

15.7.4 Key Developments 192

15.7.5 SWOT Analysis 192

15.7.6 Key Strategy 193

15.8 Caredx, Inc. 194

15.8.1 Company Overview 194

15.8.2 Financial Overview 194

15.8.3 Products Offering 195

15.8.4 Key Developments 195

15.8.5 SWOT Analysis 195

15.8.6 Key Strategy 196

15.9 Gendx 197

15.9.1 Company Overview 197

15.9.2 Financial Overview 197

15.9.3 Products Offering 197

15.9.4 Key Developments 197

15.9.5 SWOT Analysis 198

15.9.6 Key Strategy 198

15.10 Zimmer Biomet 199

15.10.1 Company Overview 199

15.10.2 Financial Overview 199

15.10.3 Products Offering 200

15.10.4 Key Developments 200

15.10.5 SWOT Analysis 200

15.10.6 Key Strategy 200

15.11 Medtronic PLC 201

15.11.1 Company Overview 201

15.11.2 Financial Overview 201

15.11.3 Products Offering 202

15.11.4 Key Developments 202

15.11.5 SWOT Analysis 202

15.11.6 Key Strategy 202

15.12 DiaSorin S.P.A 203

15.12.1 Company Overview 203

15.12.2 Financial Overview 203

15.12.3 Products Offering 204

15.12.4 Key Developments 204

15.12.5 SWOT Analysis 204

15.12.6 Key Strategy 204

15.13 Merck KGaA 205

15.13.1 Company Overview 205

15.13.2 Financial Overview 205

15.13.3 Products Offering 206

15.13.4 Key Developments 206

15.13.5 SWOT Analysis 206

15.13.6 Key Strategy 207

15.14 Immucor, Inc. 208

15.14.1 Company Overview 208

15.14.2 Financial Overview: 208

15.14.3 Products Offering 208

15.14.4 Key Developments 208

15.14.5 SWOT Analysis 209

15.14.6 Key strategy 209

16.1 Discussion Blue Print 211

16.2 Reference 214

TABLE 1 MARKET SYNOPSIS 22

TABLE 2 LIST OF ASSUMPTIONS 25

TABLE 3 PRIMARY INTERVIEWS 31

TABLE 4 GLOBAL IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION 2015-2023 (USD MILLION) 47

TABLE 5 AMERICAS TRANSPLANT DIAGNOSTICS MARKET, BY REGION 2015-2023 (USD MILLION) 48

TABLE 6 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2015-2023 (USD MILLION) 48

TABLE 7 NORTH AMERICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING

2015-2023 (USD MILLION) 48

TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 49

TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 49

TABLE 10 US IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 50

TABLE 11 US IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 50

TABLE 12 US IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 50

TABLE 13 CANADA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 51

TABLE 14 CANADA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 51

TABLE 15 CANADA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 51

TABLE 16 SOUTH AMERICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING

2015-2023 (USD MILLION) 52

TABLE 17 SOUTH AMERICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 52

TABLE 18 SOUTH AMERICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 52

TABLE 19 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2015-2023 (USD MILLION) 53

TABLE 20 EUROPE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 53

TABLE 21 EUROPE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 53

TABLE 22 EUROPE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 54

TABLE 23 GERMANY IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 54

TABLE 24 GERMANY IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 54

TABLE 25 GERMANY IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 55

TABLE 26 U.K TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 55

TABLE 27 U.K TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 55

TABLE 28 U.K TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 56

TABLE 29 FRANCE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 56

TABLE 30 FRANCE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 56

TABLE 31 FRANCE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 57

TABLE 32 SPAIN IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 57

TABLE 33 SPAIN IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 57

TABLE 34 SPAIN IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 58

TABLE 35 ITALY IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 58

TABLE 36 ITALY IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 58

(USD MILLION) 58

TABLE 37 ITALY IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 59

TABLE 38 REST OF EUROPE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING

2015-2023 (USD MILLION) 59

TABLE 39 REST OF EUROPE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 59

TABLE 40 REST OF EUROPE IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 60

TABLE 41 ASIA PACFIC TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2015-2023 (USD MILLION) 61

TABLE 42 ASIA PACIFIC IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 61

TABLE 43 ASIA PACIFIC IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 61

TABLE 44 ASIA PACIFIC IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 62

TABLE 45 CHINA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 62

TABLE 46 CHINA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 62

TABLE 47 CHINA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 63

TABLE 48 JAPAN IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 63

TABLE 49 JAPAN IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 63

TABLE 50 JAPAN IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 64

TABLE 51 INDIA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 64

TABLE 52 INDIA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 64

TABLE 53 INDIA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 65

TABLE 54 AUSTRALIA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 65

TABLE 55 AUSTRALIA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 65

TABLE 56 AUSTRALIA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 66

TABLE 57 REST OF APAC IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 66

TABLE 58 REST OF APAC IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 66

TABLE 59 REST OF APAC IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 67

TABLE 60 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY REGION 2015-2023 (USD MILLION) 68

TABLE 61 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING

2015-2023 (USD MILLION) 68

TABLE 62 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 68

TABLE 63 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 69

TABLE 64 MIDDLE EAST IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 69

TABLE 65 MIDDLE EAST IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG

2015-2023 (USD MILLION) 69

TABLE 66 MIDDLE EAST IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 70

TABLE 67 AFRICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY MOLECULAR HLA TYPING 2015-2023 (USD MILLION) 70

TABLE 68 AFRICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY IMMUNOSUPPRESSANT DRUG 2015-2023 (USD MILLION) 70

TABLE 69 AFRICA IMMUNOSUPPRESSANT DRUG MONITORING MARKET, BY TEST TYPE 2015-2023 (USD MILLION) 71

TABLE 70 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 73

TABLE 71 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 74

TABLE 72 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 74

TABLE 73 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 74

TABLE 74 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 75

TABLE 75 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 75

TABLE 76 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION 2015-2023 (USD MILLION) 75

TABLE 77 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY REGION 2015-2023 (USD MILLION) 76

TABLE 78 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE AND SERVICES, BY REGION 2015-2023 (USD MILLION) 76

TABLE 79 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 78

TABLE 80 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANT SCREENING, BY REGION 2015-2023 (USD MILLION) 79

TABLE 81 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANT SCREENING, BY REGION 2015-2023 (USD MILLION) 79

TABLE 82 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 81

TABLE 83 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY, BY REGION 2015-2023 (USD MILLION) 82

TABLE 84 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR LIVER, BY REGION 2015-2023 (USD MILLION) 82

TABLE 85 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR HEART, BY REGION 2015-2023 (USD MILLION) 83

TABLE 86 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR LUNG, BY REGION 2015-2023 (USD MILLION) 83

TABLE 87 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS, BY REGION 2015-2023 (USD MILLION) 83

TABLE 88 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 85

TABLE 89 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 86

TABLE 90 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION 2015-2023 (USD MILLION) 86

TABLE 91 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION 2015-2023 (USD MILLION) 86

TABLE 92 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 88

TABLE 93 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR COMMERCIAL SERVICE PROVIDERS, BY REGION 2015-2023 (USD MILLION) 89

TABLE 94 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION

2015-2023 (USD MILLION) 89

TABLE 95 GLOBAL TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES AND ACADEMIC INSTITUTES, BY REGION

2015-2023 (USD MILLION) 89

TABLE 96 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY REGION 2015-2023 (USD MILLION) 91

TABLE 97 AMERICAS TRANSPLANT DIAGNOSTICS MARKET, BY REGION 2015-2023 (USD MILLION) 92

TABLE 98 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2015-2023 (USD MILLION) 93

TABLE 99 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 93

TABLE 100 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 94

TABLE 101 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 94

TABLE 102 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 94

TABLE 103 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 94

TABLE 104 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 95

TABLE 105 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 95

TABLE 106 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 95

TABLE 107 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 96

TABLE 108 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 96

TABLE 109 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 96

TABLE 110 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 97

TABLE 111 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 97

TABLE 112 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 97

TABLE 113 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 97

TABLE 114 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 98

TABLE 115 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 98

TABLE 116 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 98

TABLE 117 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 99

TABLE 118 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 99

TABLE 119 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 99

TABLE 120 U.S. TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 100

TABLE 121 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 100

TABLE 122 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 100

TABLE 123 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 101

TABLE 124 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 101

TABLE 125 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 101

TABLE 126 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 101

TABLE 127 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 102

TABLE 128 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 102

TABLE 129 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 102

TABLE 130 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 103

TABLE 131 CANADA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 103

TABLE 132 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 104

TABLE 133 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 104

TABLE 134 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 104

TABLE 135 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 104

TABLE 136 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 105

TABLE 137 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 105

TABLE 138 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 105

TABLE 139 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 106

TABLE 140 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 106

TABLE 141 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 106

TABLE 142 SOUTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 107

TABLE 143 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2015-2023 (USD MILLION) 108

TABLE 144 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 109

TABLE 145 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 109

TABLE 146 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 109

TABLE 147 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 109

TABLE 148 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 110

TABLE 149 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 110

TABLE 150 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 110

TABLE 151 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 111

TABLE 152 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 111

TABLE 153 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 111

TABLE 154 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 112

TABLE 155 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 112

TABLE 156 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 112

TABLE 157 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 113

TABLE 158 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 113

TABLE 159 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 113

TABLE 160 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 113

TABLE 161 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 114

TABLE 162 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 114

TABLE 163 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 114

TABLE 164 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 115

TABLE 165 GERMANY TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 115

TABLE 166 U.K TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 116

TABLE 167 U.K TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 116

TABLE 168 U.K TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 116

TABLE 169 U.K TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 116

TABLE 170 U.K TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 117

TABLE 171 U.K TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 117

TABLE 172 U.K TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 117

TABLE 173 U.K TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 118

TABLE 174 U.K TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 118

TABLE 175 U.K TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 118

TABLE 176 U.K TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 119

TABLE 177 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 119

TABLE 178 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 119

TABLE 179 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 120

TABLE 180 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 120

TABLE 181 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 120

TABLE 182 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 120

TABLE 183 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 121

TABLE 184 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 121

TABLE 185 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 121

TABLE 186 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 122

TABLE 187 FRANCE TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 122

TABLE 188 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 123

TABLE 189 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 123

TABLE 190 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 123

TABLE 191 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 123

TABLE 192 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 124

TABLE 193 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 124

TABLE 194 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 124

TABLE 195 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 125

TABLE 196 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 125

TABLE 197 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 125

TABLE 198 SPAIN TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 126

TABLE 199 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 126

TABLE 200 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 126

TABLE 201 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 127

TABLE 202 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 127

TABLE 203 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 127

TABLE 204 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 127

TABLE 205 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 128

TABLE 206 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 128

TABLE 207 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 128

TABLE 208 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 129

TABLE 209 ITALY TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 129

TABLE 210 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 130

TABLE 211 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 130

TABLE 212 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 130

TABLE 213 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 130

TABLE 214 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 131

TABLE 215 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 131

TABLE 216 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 131

TABLE 217 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 132

TABLE 218 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 132

TABLE 219 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 132

TABLE 220 REST OF EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 133

TABLE 221 ASIA PACFIC TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2015-2023 (USD MILLION) 134

TABLE 222 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 135

TABLE 223 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 135

TABLE 224 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 135

TABLE 225 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 136

TABLE 226 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 136

TABLE 227 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 136

TABLE 228 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 136

TABLE 229 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 137

TABLE 230 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 137

TABLE 231 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 137

TABLE 232 ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 138

TABLE 233 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 138

TABLE 234 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 138

TABLE 235 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 139

TABLE 236 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 139

TABLE 237 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 139

TABLE 238 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 139

TABLE 239 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 140

TABLE 240 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 140

TABLE 241 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 140

TABLE 242 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 141

TABLE 243 CHINA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 141

TABLE 244 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 142

TABLE 245 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 142

TABLE 246 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 142

TABLE 247 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 142

TABLE 248 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 143

TABLE 249 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 143

TABLE 250 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 143

TABLE 251 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 144

TABLE 252 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 144

TABLE 253 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 144

TABLE 254 JAPAN TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 145

TABLE 255 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 145

TABLE 256 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 145

TABLE 257 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 146

TABLE 258 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 146

TABLE 259 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 146

TABLE 260 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 146

TABLE 261 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 147

TABLE 262 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 147

TABLE 263 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 147

TABLE 264 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 148

TABLE 265 INDIA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 148

TABLE 266 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 149

TABLE 267 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 149

TABLE 268 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 149

TABLE 269 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 149

TABLE 270 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 150

TABLE 271 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 150

TABLE 272 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 150

TABLE 273 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 151

TABLE 274 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 151

TABLE 275 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 151

TABLE 276 AUSTRALIA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 152

TABLE 277 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 152

TABLE 278 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 152

TABLE 279 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 153

TABLE 280 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 153

TABLE 281 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 153

TABLE 282 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 153

TABLE 283 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 154

TABLE 284 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 154

TABLE 285 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 154

TABLE 286 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 155

TABLE 287 REST OF ASIA PACIFIC TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 155

TABLE 288 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2015-2023 (USD MILLION) 156

TABLE 289 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 157

TABLE 290 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 157

TABLE 291 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 157

TABLE 292 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 157

TABLE 293 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 158

TABLE 294 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 158

TABLE 295 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 158

TABLE 296 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 159

TABLE 297 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 159

TABLE 298 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 159

TABLE 299 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 160

TABLE 300 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 160

TABLE 301 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 160

TABLE 302 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 161

TABLE 303 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 161

TABLE 304 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 161

TABLE 305 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 161

TABLE 306 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 162

TABLE 307 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 162

TABLE 308 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 162

TABLE 309 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 163

TABLE 310 MIDDLE EAST TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 163

TABLE 311 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2015-2023 (USD MILLION) 164

TABLE 312 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY REAGENTS & CONSUMABLES 2015-2023 (USD MILLION) 164

TABLE 313 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY ASSAY & KITS 2015-2023 (USD MILLION) 164

TABLE 314 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY MOLECULAR ASSAY 2015-2023 (USD MILLION) 164

TABLE 315 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY PCR-BASED ASSAY 2015-2023 (USD MILLION) 165

TABLE 316 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY SEQUENCING-BASED ASSAY 2015-2023 (USD MILLION) 165

TABLE 317 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2015-2023 (USD MILLION) 165

TABLE 318 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2015-2023 (USD MILLION) 166

TABLE 319 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2015-2023 (USD MILLION) 166

TABLE 320 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY DIAGNOSTIC APPLICATIONS 2015-2023 (USD MILLION) 166

TABLE 321 AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2015-2023 (USD MILLION) 167

TABLE 322 GLOBAL TRANSPLANT DIAGNOSTIC MARKET: KEY DEVELOPMENT 171



FIGURE 1 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: MARKET STRUCTURE 26

FIGURE 2 RESEARCH METHODOLOGY 28

FIGURE 3 DATA TRIANGULATION METHOD 33

FIGURE 4 TOP DOWN & BOTTOM UP APPROACH 34

FIGURE 5 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: MICHAEL PORTER'S FIVE FORCES MODEL 42

FIGURE 6 GLOBAL TRANSPLANT DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS 44

FIGURE 7 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS AND SERVICES 2017 & 2023 (USD MILLION) 74

FIGURE 8 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY SCREENING TYPE 2017 & 2023 (USD MILLION) 78

FIGURE 9 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY ORGAN TYPE 2017 & 2023 (USD MILLION) 82

FIGURE 10 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION 2017 & 2023 (USD MILLION) 85

FIGURE 11 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY END USER 2017 & 2023 (USD MILLION) 88

FIGURE 12 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, BY REGION 2017 & 2023 (USD MILLION) 91

FIGURE 13 AMERICAS TRANSPLANT DIAGNOSTICS MARKET, BY REGION 2017 & 2023 (USD MILLION) 92

FIGURE 14 NORTH AMERICA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2017 (%) 93

FIGURE 15 EUROPE TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2017 (%) 108

FIGURE 16 ASIA PACFIC TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2017 & 2023 (USD MILLION) 135

FIGURE 17 MIDDLE EAST & AFRICA TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY 2017 & 2023 (USD MILLION) 156

FIGURE 18 GLOBAL TRANSPLANT DIAGNOSTIC MARKET, MARKET SHARE ANALYSIS 2017 (%) 169

FIGURE 19 GLOBAL TRANSPLANT DIAGNOSTIC MARKET COMPETITIVE LANDSCAPE (%) 170



 Report Infographic image

 Global Transplant Diagnostics Market: Competitive Landscape


Thermo Fisher Scientific Inc., F. Hoffmann La Roche Ltd., Bio-Rad Laboratories, Inc., QIAGEN N.V., Illumina, Inc., bioMérieux S.A., and Becton Dickinson and Company collectively accounted for more than 45% of the market share of the global transplant diagnostics market in 2017. These companies continue to retain their strong global presence through expansions, mergers and acquisitions, and extensive product portfolio.


The global transplant diagnostics market is currently dominated by Thermo Fisher Scientific Inc. with 21.1% of the total market share. Thermo Fisher Scientific with its technically magnificent products and skilled workforce assists its customers to accelerate life science research as well as to get better outcomes in challenging clinical research fields. Through their premier brands Thermo Scientific, Invitrogen, Fisher Scientific Applied Biosystems, and Unity Lab Services cater to several products such as analytical instruments, laboratory supply chain programs and e-commerce, laboratory equipment, lab services, specialty diagnostics, and others

Hoffmann-La Roche Ltd. was the second largest medical device company, with a share of 15% as of 2016. This can be attributed to its product, the Elecsys Immunosuppressive Drug (ISD) assays which is one of the diagnostic assays having high demand in this market. The company has a huge brand image, broad product portfolio, and strong distribution network around the globe. The firm also develops and manufactures pharmaceutical, medical, and diagnostic products. Roche is known for its technological innovations in the transplant diagnostics market.


Becton, Dickinson, and Company accounted for a considerable market share of the global transplant diagnostics market. The large share of the company is attributed to the high demand for blood collection tubes and diagnostic techniques globally. Moreover, this company has a strong sales and distribution network and also provides after-sales services.


Bio-Rad Laboratories, Inc. accounted for 5.5% of the global market share in the transplant diagnostics market in 2017. Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for life science research and clinical diagnostic markets. It operates through two segments, namely life science and clinical diagnostics. The company operates in Europe, the Pacific Rim, the US, and internationally.


QIAGEN N.V. accounted for 4.9% of the global market share in the transplant diagnostics market in 2017. The company provides insight solutions regarding biological materials worldwide. Moreover, it offers assay technology solutions, DNA purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, and PCR sequencing. It serves molecular diagnostics, applied testing, pharma, and academic customers. 


In the global transplant diagnostics market, more than 200 companies are involved in the manufacturing of various types of diagnostic catheters and instrumentation. Hence, the market is not completely dominated by any one or two players but fairly divided among the top medical device manufacturing companies. Many leading players are focusing on the American and European markets owing to well-established markets, huge patient population, and high healthcare expenditures. These players have expanded their market in other regions as well. Major companies have a huge brand identity and product portfolio. These companies have adopted organic strategies such as product launches and acquisitions to gain the market. These strategies implied by players in this market are for the continuous innovation and development of new and better products to beat the opponents and strive in this big market.